Literature DB >> 18812735

The myocardial protection of HTK cardioplegic solution on the long-term ischemic period in pediatric heart surgery.

Jinping Liu1, Zhengyi Feng, Ju Zhao, Bo Li, Cun Long.   

Abstract

Cardioplegic reperfusion during a long term ischemic period interrupts cardiac surgery and also increase cellular edema due to repeated administration. We reviewed the clinical experiences on myocardial protection of one single perfusion with histidine-ketoglutarate-tryptophan (HTK) for infants. This retrospective study included 118 infants who underwent open-heart surgery between January 2004 and December 2007. We divided the entire cohort into two groups: In group H (n = 63), myocardial protection was carried out with one single perfusion with HTK solution, and in group S (n = 55) with conventional St. Thomas crystalloid cardioplegia. The duration of cardiopulmonary bypass (CPB) did not differ between these two groups, but the duration of aortic cross-clamping time in group H was significantly shorter than that in group S (p < 0.05). During reperfusion, the spontaneous re-beating rate was higher in group H (p < 0.05). There were no differences in doses of inotropic agent and creatinekinase (CK) values on postoperative day 1 between these two groups, but the level of CK in group H was significantly less than that in group S on postoperative day 2 (p < 0.01). The mortality in group H was lower than in group S (p < 0.05). The HTK group had shorter cross-clamping time and more frequent spontaneous defibrillation than St. Thomas group. We propose that HTK is valid for some complicated cardiac surgeries with long term cross-clamping time.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18812735     DOI: 10.1097/MAT.0b013e318188b86c

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   2.872


  13 in total

Review 1.  Is there a rationale for short cardioplegia re-dosing intervals?

Authors:  Yves D Durandy
Journal:  World J Cardiol       Date:  2015-10-26

Review 2.  Custodiol for myocardial protection and preservation: a systematic review.

Authors:  J James B Edelman; Michael Seco; Ben Dunne; Shannon J Matzelle; Michelle Murphy; Pragnesh Joshi; Tristan D Yan; Michael K Wilson; Paul G Bannon; Michael P Vallely; Jurgen Passage
Journal:  Ann Cardiothorac Surg       Date:  2013-11

3.  Myocardial protection during minimally invasive mitral valve surgery: strategies and cardioplegic solutions.

Authors:  Jens Garbade; Piroze Davierwala; Joerg Seeburger; Bettina Pfannmueller; Martin Misfeld; Michael A Borger; Friedrich-Wilhelm Mohr
Journal:  Ann Cardiothorac Surg       Date:  2013-11

4.  International pediatric perfusion practice: 2011 survey results.

Authors:  Brian Harvey; Kenneth G Shann; David Fitzgerald; Brian Mejak; Donald S Likosky; Luc Puis; Robert A Baker; Robert C Groom
Journal:  J Extra Corpor Technol       Date:  2012-12

5.  Custodiol Cardioplegia: A Single-Dose Hyperpolarizing Solution.

Authors:  Claus J Preusse
Journal:  J Extra Corpor Technol       Date:  2016-06

Review 6.  Blood Versus Crystalloid Cardioplegia in Pediatric Cardiac Surgery: A Systematic Review and Meta-analysis.

Authors:  Konstantinos S Mylonas; Aspasia Tzani; Panagiotis Metaxas; Dimitrios Schizas; Vasileios Boikou; Konstantinos P Economopoulos
Journal:  Pediatr Cardiol       Date:  2017-09-25       Impact factor: 1.655

7.  Clinical comparative analysis of histidine-tryptophan-ketoglutarate solution and St. Thomas crystalloid cardioplegia: A 12-year study from a single institution.

Authors:  Ying-Zhong Lin; Jing-Bin Huang; Xiang-Wei Li; Xian-Ming Tang; Wei-Jun Lu; Zhao-Ke Wen; Jian Liang; Dian-Yuan Li; Hao Wang
Journal:  Exp Ther Med       Date:  2017-07-19       Impact factor: 2.447

8.  Arterial Switch Operation and Plasma Biomarkers: Analysis and Correlation with Early Postoperative Outcomes.

Authors:  Raffaele Giordano; Massimiliano Cantinotti; Luigi Arcieri; Vincenzo Poli; Vitali Pak; Bruno Murzi
Journal:  Pediatr Cardiol       Date:  2017-05-08       Impact factor: 1.655

9.  Type of cardioplegic solution as a factor influencing the clinical outcome of open-heart congenital procedures.

Authors:  Michał Sobieraj; Marta Kilanowska; Piotr Ładziński; Irina Garbuzowa; Michał Wojtalik; Jerzy Moczko; Wojciech Mrówczyński
Journal:  Kardiochir Torakochirurgia Pol       Date:  2018-06-25

10.  Histidine-tryptophan-ketoglutarate solution decreases mortality and morbidity in high-risk patients with severe pulmonary arterial hypertension associated with complex congenital heart disease: an 11-year experience from a single institution.

Authors:  X W Li; Y Z Lin; H Lin; J B Huang; X M Tang; X M Long; W J Lu; Z K Wen; J Liang; D Y Li; X F Zhao
Journal:  Braz J Med Biol Res       Date:  2016-05-13       Impact factor: 2.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.